Amirali Talasaz Sells 210,000 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 210,000 shares of Guardant Health stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $109.89, for a total value of $23,076,900.00. Following the completion of the transaction, the chief executive officer owned 1,886,504 shares of the company’s stock, valued at approximately $207,307,924.56. This trade represents a 10.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amirali Talasaz also recently made the following trade(s):

• On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The stock was sold at an average price of $100.32, for a total value of $5,016,000.00.

Guardant Health Stock Performance

Shares of GH traded up $0.94 during midday trading on Friday, hitting $118.95. The company had a trading volume of 2,633,856 shares, compared to its average volume of 2,090,416. Guardant Health, Inc. has a 1 year low of $36.36 and a 1 year high of $121.01. The firm has a market capitalization of $15.77 billion, a P/E ratio of -35.09 and a beta of 1.48. The company’s 50-day simple moving average is $90.53 and its 200-day simple moving average is $98.79.

Guardant Health (NASDAQ:GH) last issued its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. During the same quarter last year, the business posted ($0.62) earnings per share. The firm’s quarterly revenue was up 39.4% compared to the same quarter last year. Equities analysts predict that Guardant Health, Inc. will post -2.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. V Square Quantitative Management LLC acquired a new stake in Guardant Health during the 4th quarter worth $27,000. Chesapeake Asset Management LLC acquired a new position in Guardant Health in the fourth quarter valued at $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Guardant Health during the fourth quarter worth about $31,000. Elyxium Wealth LLC purchased a new position in shares of Guardant Health during the fourth quarter worth about $35,000. Finally, Parallel Advisors LLC increased its position in shares of Guardant Health by 164.7% during the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after purchasing an additional 219 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. BTIG Research raised their price objective on shares of Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a report on Friday, February 20th. UBS Group reissued a “buy” rating and issued a $175.00 target price on shares of Guardant Health in a report on Friday, January 30th. Piper Sandler set a $127.00 price target on Guardant Health in a research note on Thursday. Stifel Nicolaus lifted their price target on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Finally, Barclays upped their price objective on Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Nineteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.00.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.